KR101885202B1 - Composition for preventing, improving or treating prostate disease comprising extract of Calamagrostis arundinacea as effective component - Google Patents

Abstract

The present invention relates to a composition for preventing, alleviating or treating prostate diseases comprising an extract of Calamagrostis arundinacea as an effective component. The extract of Calamagrostis arundinacea, the effective component of the present invention, reduces the weight of enlarged prostate by the prostate enlargement (BPH) and can remarkably reduce the content of testosterone and DHT in serum and prostate.

Description

[0001] The present invention relates to a composition for preventing, ameliorating or treating a prostate disease,

The present invention relates to a composition for preventing, ameliorating or treating a prostate disease, which contains an extract of Aspergillus as an active ingredient.

Prostate is the organ that produces various secretions to keep the urethra from drying out. It is closely related to the male hormone, androgens. As the secretion increases, the size of the prostate increases in the 20s and 30s. This is called benign prostatic hyperplasia and it is difficult to cure it because the risk of side effects is high even if the size is returned to normal by the hormone treatment and soon after stopping the hormone treatment.

Representative diseases that occur in the prostate gland include enlarged prostate, chronic prostatitis, and prostate cancer. Prostate cancer is a disease caused by bacterial infections, inflammatory or chronic pain, and prostate cancer is a malignant tumor in the relatively outer part of the prostate gland. According to a US study, It accounts for about 35% of all male cancer patients and is said to increase by 2-3% every year. The incidence in Korea is three per 100,000 people, yet it is not worrisome yet, but it is gradually increasing with the western dietary life and the rapidly aging population.

On the other hand, benign prostatic hyperplasia (BPH) is a disease in which the urethral prostate "ganglion" is enlarged due to aging and the imbalance of sex hormones, resulting in urinary symptoms due to the pressure of the urethra. It is a male disease. Recently, the rate of growth of patients with hyperplasia of the prostate in Korea has been steadily increasing to more than 20% every year. It is caused by excessive proliferation of smooth muscle and epithelial part of the prostate transplantation part, , Which is known to be due to anatomical occlusion by the enlarged prostate and functional occlusion by the? 1 -receptor which contracts the prostate smooth muscle. The main symptoms of occlusion include urinary tract weakness or weak urine stem or urine, delayed urination to wait for a long time to start urinating, discontinuation of urination to stop irrespective of urinary incontinence, terminal urination dropping like urine drops, This is representative. It is known that the testosterone (T) and the dihydrotestosterone (DHT) are involved in the typical mechanism of the various mechanisms of prostate hypertrophy.

On the other hand, room saepul (Calamagrostis arundinacea is one of the most common species of paddy in Korea and is often found in mountainous meadows, but it lives mainly in bright forests and forest edges. In addition, since the size and external shape of the plant varies greatly depending on the habitat environment, it is a species that is hesitated to classify as 'this is a plant' in the field. Basically, it is more common in relatively dry environments than in wet environmental conditions. Some individuals are very dwarf, but they are strong. It is also known to accumulate zinc in the roots and the leaves resemble birds, but the inflorescence is gathered and straightened, and the small flower ears Small) is less than 1cm, gives a very soft feeling. The atmosphere of the inflorescence is similar to that of the root. The genus Calamagrostis is a compound of the calamos derived from Greek and the Agrostis derived from Latin.

Korean Patent No. 1653492 discloses a composition for treating inflammation or enlargement of the prostate gland, which comprises a bee flower leaf extract or a fraction thereof as an active ingredient and is known as a composition for prevention, improvement or treatment of prostate disease, Patent No. 5191525 discloses that at least one natural product selected from olam, yellow umbrella, and lily of the valley is known as a testosterone 5α-reductase inhibitor and an androgen receptor binding inhibitor. However, in the prevention of prostate disease , Compositions for improvement or treatment have not been disclosed.

The present invention provides a composition for preventing, ameliorating or treating a prostate disease comprising an extract of Aspergillus odorus as an active ingredient, and the present invention provides a composition for preventing, improving or treating a prostate disease, The present invention has been accomplished by confirming that the weight of the enlarged prostate can be reduced by hypertrophy (BPH) and the content of testosterone and DHT in serum and prostate can be significantly reduced.

In order to accomplish the above object, the present invention provides a pharmaceutical composition for preventing or treating a prostate disease comprising an extract of Calamagrostis arundinacea as an active ingredient.

The present invention also provides an agent for improving dysuria caused by hypertrophy of the prostate, which comprises the above pharmaceutical composition as an active ingredient.

The invention also saepul chamber (Calamagrostis The present invention provides a health functional food composition for preventing or ameliorating a prostate disease, which comprises an extract of Arundinacea as an active ingredient.

The present invention relates to a composition for preventing, ameliorating or treating a prostate disease comprising an extract of Aspergillus oryzae as an active ingredient, wherein the extract of the effective ingredient of the present invention, which is an effective ingredient of the present invention, And significantly reduce the content of testosterone and DHT in serum and prostate, so that it can be effectively applied to prostate diseases such as benign prostatic hyperplasia, prostatitis or prostate cancer.

Fig. 1 shows the result of checking the weight change of the prostate according to the administration of the extract of the present invention. NC is a negative control; BPH is the cause of benign prostatic hyperplasia; BPH + CA is an effective treatment for benign prostatic hyperplasia; BPH + F is a group of benign prostatic hyperplasia-induced and positive control, Finasteride.
FIG. 2 shows the results of confirming changes in the DHT content in serum according to the administration of the extract of the present invention. NC is a negative control; BPH is the cause of benign prostatic hyperplasia; BPH + CA is an effective treatment for benign prostatic hyperplasia; BPH + F is a group of benign prostatic hyperplasia-induced and positive control, Finasteride.
FIG. 3 shows the result of confirming the change in the content of testosterone in the serum according to the administration of the extract of the present invention. NC is a negative control; BPH is the cause of benign prostatic hyperplasia; BPH + CA is an effective treatment for benign prostatic hyperplasia; BPH + F is a group of benign prostatic hyperplasia-induced and positive control, Finasteride.
FIG. 4 shows H & E staining results of the prostate tissue according to the administration of the extract of the present invention. NC is a negative control; BPH is the cause of benign prostatic hyperplasia; BPH + CA is an effective treatment for benign prostatic hyperplasia; BPH + F is a group of benign prostatic hyperplasia-induced and positive control, Finasteride.
FIG. 5 shows the results of examining changes in ALT and AST contents in the liver upon administration of the extract of Seedlings of the present invention. NC is a negative control; BPH is the cause of benign prostatic hyperplasia; BPH + CA is an effective treatment for benign prostatic hyperplasia; BPH + F is a group of benign prostatic hyperplasia-induced and positive control, Finasteride.

The invention saepul chamber (Calamagrostis The present invention relates to a pharmaceutical composition for preventing or treating prostate disease, which comprises an extract of arundinacea as an active ingredient.

The prostate disease is preferably benign prostatic hyperplasia, prostate cancer or prostatitis, but it is not limited thereto, more preferably it is benign prostatic hyperplasia, and may include hair loss or urination disorder due to enlarged prostate.

The Seaweed extract can be produced by a method including, but not limited to, the following steps:

(1) extracting an extractant by adding an extraction solvent to the extract;

(2) filtering the extract of step (1); And

(3) The step of extracting the filtered extract of step (2) by concentration under reduced pressure and drying.

In the step (1), the extraction solvent is preferably selected from water, a C ₁ -C ₄ lower alcohol or a mixture thereof, more preferably a C ₁ -C ₄ lower alcohol, even more preferably 99% (v / v) methanol, but is not limited thereto.

In the above production method, any conventional method known in the art such as filtration, hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction may be used. The extraction solvent is preferably added in an amount of 1 to 20 times, more preferably 5 to 15 times the weight of the dried seedling. The extraction temperature is preferably 4 to 50 DEG C, but is not limited thereto. The extraction time is preferably 0.5 to 10 hours, more preferably 0.5 to 5 hours, but not always limited thereto. In the above method, it is preferable to use a vacuum decompression concentrator or a vacuum rotary evaporator for the decompression concentration in the step (3), but it is not limited thereto. The drying is preferably performed under reduced pressure, vacuum drying, boiling, spray drying or freeze drying, but not always limited thereto.

The Sephadex extract may reduce the content of DHT (dihydrotestosterone) or testosterone in serum.

The pharmaceutical composition of the present invention may further comprise a carrier, an excipient or a diluent in addition to the above-mentioned extract.

The pharmaceutical composition of the present invention may be administered orally or parenterally, and it is preferable to use an intravenous or intraperitoneal, rectal, intravenous, intramuscular, subcutaneous, intrauterine, or intracerebral injection method during parenteral administration.

The pharmaceutical composition of the present invention can be prepared using a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient. Solid formulations for oral administration include tablets, pills, powders, granules, capsules, and the like, which may contain one or more excipients such as starch, calcium carbonate, sucrose or lactose lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like may also be used. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like. Examples of suppositories include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

The composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level will depend on the type of disease, severity, , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including co-administered drugs, and other factors well known in the medical arts. The composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or in multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, which can be easily determined by those skilled in the art.

The dosage of the composition of the present invention may be varied depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of disease.

The present invention also relates to an agent for improving dysuria caused by hypertrophy of the prostate, which comprises the above pharmaceutical composition as an active ingredient.

The invention also saepul chamber (Calamagrostis The present invention relates to a health functional food composition for preventing or ameliorating a prostate disease containing an extract of arundinacea as an active ingredient.

The health functional food composition for preventing or ameliorating a prostate disease, which comprises the extract as an active ingredient, is prepared from any one selected from a beverage, a ring, a tablet, a capsule, and a powder, And can be suitably produced according to a conventional method.

Examples of foods to which the extract of the present invention can be added include meat products, sausages, bread, chocolate, candies, snacks, confectionery, pizza, ramen noodles, other noodles, dairy products including ice- , Tea, a drink, an alcoholic beverage, and a vitamin complex, and includes all the health functional foods in a conventional sense.

The health functional foods include various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, colorants and enhancers (cheese, chocolate etc.), pectic acid and its salts, alkynic acid and its salts, , pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. It may also contain flesh for the production of natural fruit juices and vegetable drinks. These components may be used independently or in combination.

The health functional food composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient. The natural carbohydrates are sugar saccharides such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not limited thereto.

Example  1. Room outpost , 037-065) Preparation of extract

7.37g of the extract was obtained from Korean Plant Extract Bank at an extraction yield of 6.0% using 99.9% (v / v) methanol grade (HPLC grade) as an extraction solvent. ( in vivo ).

Example  2. Production and statistical analysis of animal models

After 10-week-old male Wister rats (central laboratory animals) were purified for 1 week, the prostate hypertrophy group (BPH) was injected with 3 mg / kg of testosterone propionate (TP) Respectively. In the group treated with the extract, the oral administration of 100 mg / kg of Zygomycorr japonicum extract was administered orally for 4 weeks before TP injection. The positive control group was treated with 10 mg / kg of Finasteride, a 5α-reductase inhibitor used as a treatment for benign prostatic hyperplasia Lt; / RTI >

Statistical analysis was performed with ANOVA, with # being statistically significant when compared to normal ( P <0.05); * Indicates a statistically significant difference compared to the BPH group, and P <0.05.

Example  3. Prostate Weighing

The rats were injected subcutaneously with testosterone propionate (TP) for 4 weeks to induce hypertrophy of the prostate gland, and oral administration of finasteride (Finasteride), which is used as a therapeutic agent for the growth of the prostate gland and enlargement of the prostate gland, for 4 weeks. After the administration of the drug, sacrificed rat prostate glands were sampled and weighed.

As a result, as shown in Fig. 1, BPH + CA, prostatic hyperplasia + Finasteride group: BPH + prostate hyperplasia + F), the weight of the prostate gland in the group that caused the hyperplasia of the prostate gland increased compared with that of the normal group, and the weight of the prostate gland significantly decreased Respectively.

Example  4. Prostate DHT  change

After the end of the experiment, the separated blood was centrifuged at 4,000 rpm for 20 minutes to check the content of DHT (dihydrotestosterone) in an enlarged prostate animal model. The supernatant was taken from the serum, and the serum was measured using an ELISA kit (ALPCO, Salem) The content of DHT (dihydrotestosterone) was measured.

As a result, as shown in FIG. 2, it was confirmed that the content of DHT (dihydrotestosterone) in serum was statistically significantly decreased in the group administered with the extract of Seedlings.

Example  5. Serum Testosterone  Analysis of content change

After the end of the experiment, the separated blood was centrifuged at 4,000 rpm for 20 minutes, and the supernatant was taken. The serum was analyzed by ELISA kit (Cayman, USA) for the testosterone (testosterone ) Were measured.

As a result, as shown in FIG. 3, the testosterone content in serum decreased statistically significantly in the group administered with the extract of Seedlings.

Example  6. Histopathological changes of the prostate gland

After the end of the experiment, the extracted prostate gland was fixed with 10% neutral buffered formalin for 24 hours and paraffin embedding was performed. The embryoid tissue was cut to a thickness of 4 μm and cut into sections and stained with H & E (hematoxylin, Sigma-Aldrich, USA) and eosin Y (Sigma-Aldrich) And examined with an optical microscope.

As a result, as shown in FIG. 4, the height and number of epithelial cells were increased in the prostatic hyperplasia-induced group, but it was confirmed that the proliferation of the epithelial cells was inhibited in the group treated with the extract.

Example  7. Serum ALT and AST  Measure

In order to confirm the toxicity of Aspergillus oryzae extracts in an enlarged prostate animal model, the separated blood was centrifuged at 4,000 rpm for 20 minutes after the end of the experiment, and the contents of ALT and AST in the serum were determined by taking the supernatant.

As a result, as shown in FIG. 5, there was no statistically significant change in the contents of ALT and AST used as common liver toxicity index I did.

Claims (7)

A pharmaceutical composition for preventing or treating enlargement of the prostate gland comprising Calamagrostis arundinacea extract as an active ingredient. delete The pharmaceutical composition for preventing or treating enlargement of the prostate gland according to claim 1, wherein the extraction solvent of the extract is a water, a C ₁ -C ₄ lower alcohol or a mixture thereof. The pharmaceutical composition for preventing or treating enlargement of prostate gland according to claim 1, wherein the extract of Zygomycorrhizae reduces the content of DHT (dihydrotestosterone) or testosterone in serum. An agent for improving dysuria caused by hypertrophy of the prostate, which comprises the composition of any one of claims 1, 3, and 4 as an active ingredient. A functional food composition for preventing or ameliorating hyperplasia of the prostate, comprising extract of Calamagrostis arundinacea as an active ingredient. 7. The method according to claim 6, wherein the extract of Calamagrostis arundinacea is prepared by any one of formulations selected from drinks, pills, tablets, capsules and powders. Health functional food composition.

Images